Anaphore completes $25m Series A financingAnaphore, a protein therapeutics company, has completed a $25m Series A round of financing, co-led by Apposite Capital, 5AM Ventures and Versant Ventures.
The investment will be used to accelerate the development of Atrimers - a new class of protein therapeutics the company is developing for immune-mediated diseases and oncology, according to a statement.
Chris Hollowood, principal, Apposite, said, 'With innovative science in an important area of drug development, strong intellectual property and an experienced management team, we found Anaphore to be an extraordinary opportunity to rapidly create value and we look forward to their continued success.'
Established in 2006 and based in London, Apposite is a healthcare specialist investment firm.
Founded in 2002, 5AM Ventures makes seed and early stage investments in life sciences companies.
Versant is a healthcare-focused venture capital firm, specialising in early stage investments in medical devices, biotechnology and pharmaceuticals, healthcare services and healthcare IT.
Copyright © 2009 AltAssets
Article is in the following categories:
Private Equity News» By Region» North America» United States
Private Equity News» By Region» North America» United States
